moneyheap
VIR · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Vir Biotechnology, Inc. Common Stock (VIR) stock moving?
Vir's pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta met its primary endpoint. 44% of patients reached undetectable virus plus ALT normalization, versus 0% with delayed treatment. Expanded Phase 2 SOLSTICE data also showed 28 of 28 patients with undetectable HDV RNA at week 96. The shares closed at $13.645 on Nov 9, up about 11.7% from $12.21 on Nov 6, on 7.12M shares, roughly 3 to 5 times the prior sessions' volume. They then eased to $13.15 on Nov 10 (down about 3.6%) on lighter volume of 1.30M. Four analysts reiterated or raised targets in the days after the readout: Needham $20 (Nov 5), HC Wainwright $22 (Nov 9), Evercore $25 and Morgan Stanley $28 (Nov 10). Q3 showed a smaller loss per share ($0.57 vs $0.72 expected), but sales missed estimates. Cash was about $901M excluding $90M of Gilead upfront consideration. Risks: the 44% result is against deferred treatment rather than an active comparator, the full Phase 3 package and FDA filings are still to come in 2027, ECLIPSE 2 and 3 data are due in Q1 2027, and the company is not yet profitable. The 30-day price range was $10.03 to $14.38.
News behind the analysis
- Vir Biotechnology Announces Positive Topline Results from Phase 3 ECLIPSE 1 TrialThe Phase 3 ECLIPSE 1 trial met its primary and key secondary endpoints for elebsiran and tobevibart in chronic hepatitis delta. Filings are planned for 2027.
- Reported Sunday, Vir's Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment44% of patients reached undetectable virus plus ALT normalization, versus 0% in the deferred-treatment arm. The comparison is against delayed treatment, not an active comparator.
- Vir Biotech Highlights Significant Viral Suppression in Advanced Liver Disease StudyVir reported positive Phase 3 ECLIPSE 1 data for its chronic hepatitis delta treatment ahead of planned 2027 FDA filings.
- Vir Biotechnology Announced Sunday, Expanded Phase 2 SOLSTICE Data For Elebsiran, Tobevibart In Chronic Hepatitis Delta, With 100% (28/28) Undetectable HDV RNA At Week 96, 100% (10/10) Sustained Viral Response After Treatment DiscontinuationExpanded Phase 2 SOLSTICE data showed 28 of 28 patients with undetectable HDV RNA at week 96. Ten of ten patients sustained viral response after treatment discontinuation.
- Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28Morgan Stanley kept its Overweight rating and lifted its price target to $28. This is the highest target among the recent analyst updates.
- Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25Evercore ISI kept its Outperform rating and raised its price target to $25 after the Phase 3 readout.
- HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price TargetHC Wainwright reiterated its Buy rating and kept its $22 price target following the trial data.
- Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20Needham kept its Buy rating and raised its price target from $18 to $20 on Nov 5, before the Phase 3 readout.
- Vir Biotechnology Reports Third Quarter 2026 Financial ResultsVir ended the quarter with about $901M in cash and investments, excluding $90M upfront from the Gilead collaboration. VIR-5500 received FDA Fast Track designation, and ECLIPSE 2 and 3 topline data are expected in Q1 2027.
- Vir Biotechnology Q3 EPS $(0.57) Beats $(0.72) Estimate, Sales $(188.000K) Miss $127.500K EstimateQ3 loss per share of $0.57 beat the $0.72 estimate, while sales missed the estimate. The sales figure in the source is garbled, so the exact revenue is unclear.
About Vir Biotechnology, Inc. Common Stock
Vir Biotechnology is a clinical-stage biotech in San Francisco that develops immune-based medicines for serious infectious diseases and cancer. Its lead programs are a two-drug combination (tobevibart plus elebsiran) for chronic hepatitis delta, now in Phase 3 trials, and masked T-cell engager cancer drugs built on its PRO-XTEN platform, including VIR-5500 for prostate cancer, which it is developing with Astellas.
How it makes money
Vir has no meaningful product sales right now; quarterly revenue is close to zero. It pays for its work mainly through partnership deals, including upfront and milestone payments from Astellas (VIR-5500) and Gilead (a T-cell engager discovery deal), plus share offerings. It ended Q3 2026 with roughly $0.9 billion in cash and investments. Earlier in the pandemic, it earned large but temporary revenue from COVID-19 antibody partnerships.
What usually moves VIR
- Phase 3 ECLIPSE hepatitis delta trial results (ECLIPSE 1 topline expected Q4 2026)
- VIR-5500 prostate cancer data and start of pivotal trials
- Partnership milestones and new licensing deals
- Cash burn and possible share dilution
- Biotech sector sentiment and interest rates